Paper Example on Primary Decision Assessment & Treatment: Analysis of Client's Signs & Symptoms

Decision One

The primary decision that I can induce in the assessment and treatment of the client is the analysis of the signs and symptoms of the client. The reason for selecting this decision is to confirm that the symptoms are not substance abuse or medical-related (Velligan et al., 2018). It mainly involves physical means where healthcare providers can determine the delusion, hallucination, extreme disorganization, aggression, self-harm, or agitation (Velligan et al., 2018). Based on the condition of the client in the previous study, the patient was suffering from hallucination and dilution, which makes the decision suitable for the case. The expectation, in this case, was that the patient could have shown self-harm symptoms (Velligan et al., 2018). It is different because the hallucination of the client was severely displayable.

Is your time best spent reading someone else’s essay? Get a 100% original essay FROM A CERTIFIED WRITER!

Save 25%

The treatment, in this case, can be done is a self-help resource of the client where the client needs to educate herself of the illness (Tibbitts et al., 2016). In this case, the decision made on the treatment can be relieving stress, changing your diet, and seeking social support. The main achievement of the treatment approach is recovery and reduction of hallucination, which bases on the frequency and severity of symptoms and improves the way the client feels (Tibbitts et al., 2016). The results were contrary to the expectation where the hallucination of the client was severely displayed as she kept on stressing on Allah's image. The treatment conflicted with the expectation where the rate of the severity of the symptoms increased.

Decision Two

The second decision that is applicable in this case is the active phase analysis, where it mainly involves the stressful events of the client. It further entails the worsening of the prognosis with each acute episode (Velligan et al., 2018). The assessment mainly bases on the psychiatric evaluation that involves the doctor's skills and technique of the disorder. The doctor needs to look into the appearance and demeanor and further ask about the thoughts, moods, hallucinations, delusions, violence potential, and substance used (Velligan et al., 2018). The expectation of the assessment, in this case, is the client's positive response and relation towards her family members and the loved ones. It was different from the results of decision two, where the client showed a high level of depression.

The treatment, in this case, involved psychological counseling, which further involves the induction of family therapy (Crespo-Facorro et al., 2017). It involves the meeting up of family members and loved ones to advocate the patient's current situation. This treatment is expected to reduce the level of hallucination and manage it, which is different where the symptoms appeared to be critical and vital.

Decision Three

The third decision is the assessment of the residual phase, which establishes the actual illness pattern. It mainly entails the persistence in negative symptoms of the client. Here, the healthcare provider may assess the lack of prominent psychotic symptoms, but the illness is muted that stops the short of recovery (Crespo-Facorro et al., 2017). The decision is expected to examine the imagery analysis of the patient through the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (Tibbitts et al., 2016). The expectation, in this case, was an image of tumors and problems in the brain structure which lacked on the patient.

The treatment, in this case, is mainly medically based on the disorder where the antipsychotic is the commonly used drugs. The best medication preferred is the second generation, which has a low risk of side effects (Molent et al., 2019). It is important to note that the patient has to take long-acting injectable antipsychotics such as aripiprazole, fluphenazine decanoate, haloperidol decanoate, and paliperidone. The expectation was to reduce the level of side effects of the patient, which conflicted with the results (Molent et al., 2019). The key factors influencing pharmacokinetic and pharmacodynamic processes, in this case, are the absorption process where the drug passes through the barriers such as cell membranes before entering the bloodstreams (Molent et al., 2019). The other factor is the distribution process of the drug, which is also navigated by several aspects. Rate of blood flow to the tissue, the tissue membrane permeability, the tissue mass itself, and the vascular are the primary influence in this case (Molent et al., 2019). Also, the elimination stage involves the excretion of the inactive substance.

Ethical and Legal Implications Related to Prescribing Antipsychotic Therapy

It is essential for healthcare providers to review the patient's history before diagnosis and treatment processes (Ganella et al., 2018). To develop an appropriate therapeutic strategy, it is significant to learn the hopes, concerns, and motivation, which might contain psychopharmacological agents to show actual target symptoms (Ganella et al., 2018). The main aim is to prescribe psychotic medication only when there is a clear indication of strong evidence.

References

Crespo-Facorro, B., Bernardo, M., Argimon, J. M., Arrojo, M., Bravo-Ortiz, M. F., Cabrera-Cifuentes, A., ... & Olivares, J. M. (2017). Effectiveness, efficiency, and efficacy in the multidimensional treatment of schizophrenia: rethinking project. Revista de Psiquiatria y Salud Mental (English Edition), 10(1), 4-20.

Ganella, E. P., Seguin, C., Bartholomeusz, C. F., Whittle, S., Bousman, C., Wannan, C. M., ... &Zalesky, A. (2018). Risk and resilience brain networks in treatment-resistant schizophrenia. Schizophrenia Research, 193, 284-292.

Molent, C., Olivo, D., Wolf, R. C., Balestrieri, M., &Sambataro, F. (2019). Functional neuroimaging in treatment-resistant schizophrenia: A systematic review. Neuroscience & Biobehavioral Reviews.

Tibbitts, J., Canter, D., Graff, R., Smith, A., &Khawli, L. A. (2016, February). Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. In MAbs (Vol. 8, No. 2, pp. 229-245). Taylor & Francis.

Velligan, D., Carpenter, W., Waters, H. C., Gerlanc, N. M., Legacy, S. N., &Ruetsch, C. (2018). Relapse Risk Assessment for Schizophrenia Patients (RASP): A New Self-Report Screening Tool. Clinical schizophrenia & related psychoses, 11(4), 224-235.